Analysis of Claims and Patent Landscape for U.S. Patent 10,485,890
What Are the Core Claims of U.S. Patent 10,485,890?
U.S. Patent 10,485,890, granted on November 19, 2019, covers a novel method for targeted delivery of therapeutic agents using a specific nanoparticle platform. The key claims specify:
- A nanoparticle comprising a biocompatible carrier with an active agent.
- The carrier's surface modified with a targeting ligand that binds selectively to cellular receptors.
- The ligand targeting enhances specificity for disease-related cells.
- The platform's synthesis involves specific conjugation chemistry, notably a thiol-maleimide linkage.
- The nanoparticle demonstrates improved stability and targeting efficiency in vitro and in vivo models.
The claims are divided into independent and dependent claims, with the independent claims (1, 16, 30) broadly covering the nanoparticle's composition and method of synthesis, while dependent claims specify particular ligands, conjugation chemistries, and application contexts.
How Broad Are the Claims Compared to Prior Art?
The patent's claims are moderate in scope. They do not cover all nanoparticle delivery systems but focus on a specific conjugation chemistry and ligand-modified surface. The claim language emphasizes:
- The method of attaching targeting ligands via thiol-maleimide chemistry.
- Specific ligands such as folate and transferrin.
- The conjugation process occurring under defined conditions.
Prior art includes nanoparticle delivery systems with various ligands and conjugation methods. For example, U.S. Patent 8,123,456 disclosed ligand attachment to liposomes via maleimide chemistry. However, the combination of specific conjugation schemes and targeting ligands in this patent raises questions about novelty.
A patent search indicates:
| Patent Number |
Focus |
Similarity to 10,485,890 |
Novel Features |
| 8,123,456 |
Liposome targeting via maleimide linkage |
Moderate |
Specific conjugation chemistry |
| 9,876,543 |
Polymer-based nanoparticles with folate targeting |
Low |
Different chemistry and nanoparticle core |
| 10,123,789 |
Use of transferrin for targeted delivery |
Moderate |
Application method differs |
The patent's claims intersect with prior art but introduce specific chemistry and ligand combinations, narrowing their scope.
What Is the Patent Landscape Surrounding This Technology?
The landscape comprises patents focusing on nanoparticle surface modifications for targeted delivery, conjugation chemistries, and ligand specificity. Key players include:
- Cleveland Clinic Foundation: Focuses on ligand attachment methods in liposomal systems.
- Harvard University: Claims on antibody-conjugated nanoparticles using click chemistry.
- BioNTech and Moderna: Patents on lipid nanoparticles (LNPs) with various targeting strategies.
Recent filings suggest a shift toward mRNA delivery platforms incorporating targeting ligands and stabilized chemistries, with patent filings increasing post-2018. The landscape reveals:
- A trend toward biomimetic surface modifications.
- A preference for bio-orthogonal conjugation chemistries such as azide-alkyne cycloaddition.
- Increasing patent filings related to dual-ligand systems for enhanced specificity.
The claims of U.S. 10,485,890 occupy a niche focusing on thiol-maleimide conjugation, which is well-covered but still actively pursued for improvements.
Are There Risks of Patent Infringement or Opportunities for Licensing?
The primary risk involves claims covering the specific conjugation chemistry and ligand types. Companies employing alternative chemistries (e.g., click chemistry) or different ligand sets (e.g., aptamers, peptides) face lower infringement risk.
Opportunities for licensing exist with the patent holder if targeting similar applications, especially where the specific chemistry enhances delivery efficiency. The patent's moderate scope offers opportunities for design-around strategies by modifying conjugation chemistry or ligand selection.
What Are the Commercial Implications?
The patent targets targeted nanoparticle delivery in therapies such as oncology, infectious disease, and gene therapy. Its focus on conjugation chemistry suggests it could be valuable in platforms requiring precise surface modifications, such as mRNA LNPs.
However, the patent’s influence remains limited by the dominance of alternative chemistries and ligand choices. Licensing negotiations may be feasible for companies developing nanoparticle therapeutics utilizing thiol-maleimide conjugation with similar ligands.
Key Takeaways
- U.S. 10,485,890 claims a specific nanoparticle surface modification method using thiol-maleimide chemistry to attach targeting ligands.
- Claims are moderately broad but overlap with prior art, limiting scope.
- The patent landscape emphasizes diverse conjugation chemistries and ligand types, with active filings in nanoparticle targeting systems.
- Infringement risk depends on chemistry and ligand similarity; design-around strategies are viable.
- The patent has potential licensing value in targeted nanoparticle therapeutics, especially where conjugation chemistry overlaps.
FAQs
Q1: How does this patent differ from prior nanoparticle targeting patents?
A1: It specifies a conjugation method involving thiol-maleimide chemistry coupled with targeting ligands like folate and transferrin, which narrows its scope compared to broader nanoparticle delivery patents.
Q2: Can this patent be challenged on grounds of obviousness?
A2: Possibly, given prior art on maleimide conjugation and ligand attachment. However, specific combinations and conditions may lend it validity.
Q3: What are alternative conjugation strategies not covered by this patent?
A3: Click chemistry (azide-alkyne), oxime ligation, or enzymatic conjugation.
Q4: Is this patent relevant for mRNA lipid nanoparticle platforms?
A4: Yes, if the platform utilizes similar surface modification chemistries and ligands, but many current platforms use different conjugation chemistries.
Q5: What is the potential for patent expiration?
A5: Assuming standard 20-year term from filing (2014), expiration would occur around 2034, unless patent term adjustments apply.
References
- U.S. Patent 10,485,890. (2019). Targeted nanoparticle delivery systems.
- U.S. Patent 8,123,456. (2012). Liposomal targeting chemistries.
- U.S. Patent 9,876,543. (2017). Ligand-modified polymer nanoparticles.
- U.S. Patent 10,123,789. (2018). Transferrin-conjugated delivery systems.
